Share price · ALKS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALKS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 24 Sep 2026-3.2%
Nothing announced by ALKS that day or the session before.
- 18 Sep 2026-7.1%
Nothing announced by ALKS that day or the session before.
- 29 Jun 2026-4.6%
Nothing announced by ALKS that day or the session before.
- 12 May 2026+8.0%
- 5 May 2026+6.1%
- 31 Mar 2026+17.3%
Nothing announced by ALKS that day or the session before.
- 25 Feb 2026-7.0%
- 18 Feb 2026-2.7%
Nothing announced by ALKS that day or the session before.
Share of unusual movement by asset
For each asset, the share of ALKS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(6 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Schizophrenia | |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Schizophrenia | |
Diroximel fumarate(Vumerity) | Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis |
| Approved | Opioid receptorSmall molecule | Substance Use Disorder Opioid and Alcohol Dependence | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
| Phase 3 | Orexin-2 receptor (agonist)Small molecule | NarcolepsyIdiopathic Hypersomnia |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (4)
May 2027 (2)
June 2027 (1)
What to watch
September 2027 (1)
What to watch
2030 (1)
June 2030 (1)
What to watch
2034 (1)
July 2034 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $480M | $121M | $631M+ $124M short-term inv. | —$93M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $496M | $113M | $512M+ $145M short-term inv. | —$145M operating cash flow | report ↗ |
| 2026-Q1 | $393M | $103M | $352M+ $160M short-term inv. | $66M-$166M operating cash flow | report ↗ |
| 2025-Q3 | $394M | $82M | $616M+ $495M short-term inv. | —$102M operating cash flow | report ↗ |
| 2025-Q2 | $391M | $77M | $521M+ $495M short-term inv. | —$150M operating cash flow | report ↗ |
| 2025-Q1 | $307M | $72M | $400M+ $484M short-term inv. | —$99M operating cash flow | report ↗ |
| 2024-Q3 | $378M | $60M | $396M+ $513M short-term inv. | —$82M operating cash flow | report ↗ |
| 2024-Q2 | $399M | $60M | $535M+ $341M short-term inv. | —$146M operating cash flow | report ↗ |
| 2024-Q1 | $350M | $68M | $421M+ $324M short-term inv. | —$21M operating cash flow | report ↗ |
| 2023-Q3 | $381M | $97M | $648M+ $241M short-term inv. | —$100M operating cash flow | report ↗ |
| 2023-Q2 | $617M | $101M | $666M+ $163M short-term inv. | —$216M operating cash flow | report ↗ |
| 2023-Q1 | $288M | $94M | $321M+ $279M short-term inv. | $42M-$21M operating cash flow | report ↗ |
| 2022-Q3 | $252M | $100M | $264M+ $316M short-term inv. | $64M$0.6M operating cash flow | report ↗ |
| 2022-Q2 | $276M | $93M | $255M+ $326M short-term inv. | $30M-$2.3M operating cash flow | report ↗ |
| 2022-Q1 | $279M | $96M | $283M+ $246M short-term inv. | $36M$22M operating cash flow | report ↗ |
| 2021-Q3 | $294M | $118M | $310M+ $250M short-term inv. | $29M$83M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.5B | $324M | $1.1B+ $200M short-term inv. | —$521M operating cash flow | report ↗ |
For fiscal year 2025, Alkermes reported total revenues of $1,475.9M, down 5.2% YoY, with proprietary product net sales increasing approximately 9% YoY. R&D expense was $323.96M, up 32.1% YoY, and cash and equivalents totaled $1,119.78M. The company reported GAAP net income of $241.66M, or $1.43 diluted earnings per share.
For 2026, management guided to total revenues of $1,730–$1,840M, R&D expenses of $445–$485M, SG&A expenses of $890–$930M, a GAAP net loss of $115–$135M, EBITDA of $60–$90M, and adjusted EBITDA of $370–$410M. The Alixorexton Phase 3 program in narcolepsy is expected to initiate in Q1 2026, with the Phase 2 study in idiopathic hypersomnia continuing, and additional orexin candidates are planned to advance into Phase 2 in ADHD and fatigue associated with multiple sclerosis and Parkinson’s disease. The acquisition of Avadel closed in February 2026, with LUMRYZ net sales for the post-close period expected at $315–$335M for 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $1.6B | $245M | $291M+ $461M short-term inv. | —$439M operating cash flow | report ↗ |
| 2023-FY | $1.7B | $271M | $457M+ $316M short-term inv. | —$401M operating cash flow | report ↗ |
| 2022-FY | $1.1B | $394M | $292M+ $316M short-term inv. | $40M$21M operating cash flow | report ↗ |
| 2021-FY | $1.2B | $407M | $338M+ $199M short-term inv. | $12M$102M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 33 sales ($10.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-03 | Gaffin David Joseph · EVP, CLO, Alkermes, Inc. | Open-market sale | 2,035 | $46.17 | $94K | Form 4 |
| 2026-10-08 | Reed Joshua · SVP, Chief Financial Officer | Option exercise | 9,164 | — | — | Form 4 |
| 2026-10-08 | Reed Joshua · SVP, Chief Financial Officer | Tax withholding | 4,069 | $40.11 | $163K | Form 4 |
| 2026-10-08 | Reed Joshua · SVP, Chief Financial Officer | Option exercise (derivative) | 9,164 | — | — | Form 4 |
| 2026-10-07 | Whitaker Anne Clem · director | Award / grant (derivative) | 7,239 | — | — | Form 4 |
| 2026-10-07 | Whitaker Anne Clem · director | Award / grant (derivative) | 17,998 | — | — | Form 4 |
| 2026-10-02 | Gaffin David Joseph · EVP, CLO, Alkermes, Inc. | Open-market sale | 2,034 | $41.03 | $83K | Form 4 |
| 2026-09-03 | Gaffin David Joseph · EVP, CLO, Alkermes, Inc. | Open-market sale | 2,034 | $48.01 | $98K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 383 reporting institutions held 175.4M shares ($5.9B).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 28,314,410 | $1.0B |
| 2 | BAKER BROS. ADVISORS LP | 10,012,267 | $354.0M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 9,511,112 | $336.3M |
| 4 | STATE STREET CORP | 9,465,286 | $334.7M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 7,427,397 | $262.6M |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 6,160,428 | $217.8M |
| 7 | AMERICAN CENTURY COMPANIES INC | 6,072,103 | $214.7M |
| 8 | DIMENSIONAL FUND ADVISORS LP | 4,522,378 | $159.9M |
| 9 | Commodore Capital LP | 4,200,000 | $148.5M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 4,182,267 | $147.9M |
| 11 | Deep Track Capital, LP | 3,590,323 | $127.0M |
| 12 | JPMORGAN CHASE & CO | 4,101,789 | $123.7M |
| 13 | WELLINGTON MANAGEMENT GROUP LLP | 2,970,166 | $105.0M |
| 14 | FIRST TRUST ADVISORS LP | 2,968,785 | $105.0M |
| 15 | PRIMECAP MANAGEMENT CO/CA/ | 2,539,990 | $89.8M |